Halozyme Therapeutics

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 11.42% of float, squeeze risk: MODERATE

298 PubMed publications found for Halozyme

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

Translatability of a miniature pig model to predict subcutaneous clinical injection times with a high-volume auto-injector and recombinant human hyaluronidase.

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.

Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.

Short interest: 12.26% of float, squeeze risk: MODERATE

Dilution score: 11/100 (LOW), 999.0 months cash

299 PubMed publications found for Halozyme

Congress: 0 buys, 0 sells (1 total trades)

SW convergence: 36/100 (Bearish Convergence), 1 bullish / 1 bearish signals

297 PubMed publications found for Halozyme

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.

Short interest: 12.32% of float, squeeze risk: MODERATE

Short interest: 12.22% of float, squeeze risk: MODERATE

<article class="bts-verified-summary" data-ticker="HALO">
<p>Halozyme Therapeutics (HALO) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-2">[2]</a></sup>, including 1 Phase 3<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>Trial NCT06689085<sup><a href="#fn-3">[3]</a></sup> evaluates Testosterone enanthate in Hypogonadism, Male with a target enrollment of 100 participants.</p>
<p>HALO has 3 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-4">[4]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Halozyme+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Halozyme+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">ClinicalTrials.gov · NCT06689085 (2026-02-18) <a href="https://clinicaltrials.gov/study/NCT06689085" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-4">SEC EDGAR · 0001159036 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22HALO%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

ClinicalTrials.gov — NCT06689085

SEC EDGAR — 0001159036

Halozyme Therapeutics (HALO) — BioTechSigns Verified Summary

Halozyme Therapeutics (HALO) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 3[1].

Trial NCT06689085[3] evaluates Testosterone enanthate in Hypogonadism, Male with a target enrollment of 100 participants.

HALO has 3 Form 4 insider filings recorded at the SEC in the past 30 days[4].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Halozyme+Therapeutics%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Halozyme+Therapeutics%22&aggFilters=status%3Arec%2Cact
[3] ClinicalTrials.gov, NCT06689085. Source last updated 2026-02-18, retrieved 2026-04-11.
    https://clinicaltrials.gov/study/NCT06689085
[4] SEC EDGAR, 0001159036. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22HALO%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

This is a 52-week open label single arm study + 24-Month long-term safety extension to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism.

The study aims to determine the effectiveness of XYOSTED measured by continuation or induction of puberty in addition to XYOSTED dosage, safety and testosterone levels.